The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Advanced Therapeutics Pharmaceutical Outsourcing Global Market Report 2024, the advanced therapeutics pharmaceutical outsourcing market is expected to show promising growth in the forecast period.

Market Expansion Overview

• 2023 Market Size: $7.64 billion
• 2024 Market Size: $8.07 billion
• CAGR: 5.6%

The advanced therapeutics pharmaceutical outsourcing market has seen significant growth, driven by the expansion of biopharmaceutical infrastructure, regulatory compliance, demand for novel drugs, improved efficiency, and personalized medicine.

Future Market Projections

• 2028 Market Size: $9.76 billion
• CAGR:9%

Steady growth is expected due to increased adoption of cell and gene therapies, focus on mRNA therapies, demand for cutting-edge treatments, cost-effective outsourcing solutions, and collaborative innovation. Trends include technological advancement, expertise in advanced therapeutics, innovative therapy pipelines, and rapid advancements in gene, cell, and mRNA technologies.

View More On The Advanced Therapeutics Pharmaceutical Outsourcing Market Report 2024 – https://www.thebusinessresearchcompany.com/report/advanced-therapeutics-pharmaceutical-outsourcing-global-market-report

Impact of Cell and Gene Therapies

• Increase in Gene Therapy Patients: From 16,244 in 2020 to 94,696 in 2025

The adoption of cell and gene therapies is driving market growth. These therapies use living cells or genetic material to treat diseases, with outsourcing providing access to experienced providers. According to a 2023 Nature report, the number of patients treated with gene therapies is expected to increase significantly by 2025.

Key Market Players

• Major Companies: Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, IQVIA, ICON plc, SGS SA, Lonza Group, Parexel International Corporation, WuXi AppTec, Syneos Health, Catalent Inc., Charles River Laboratories International, Recipharm AB, Croda International Plc, Samsung Biologics.

Strategic Partnerships

• Example Partnership: Lonza and Context Therapeutics Inc. (January 2023)

Companies are forming strategic partnerships to provide reliable services. For example, Lonza partnered with Context Therapeutics Inc. to offer manufacturability assessment, gene and cell line construction, and process development for drug substances and products.

Acquisitions and Expansions

• Notable Acquisition: Catalent Inc. acquires Metrics Contract Services and CDMO (August 2022)

Catalent Inc. acquired Metrics Contract Services and CDMO for $475 million to enhance its capabilities in oral solid formulation development, manufacturing, and packaging, helping customers accelerate their programs and handle potent compounds.

Market Segmentation

• By Service Type: Contract Research Organizations (CROs), Contract Development and Manufacturing Organizations (CDMOs)
• By Indication: Oncology, Neurology, Cardiology, Infectious Diseases, Other Indications
• By Therapy: Cell Therapy, Gene Therapy, RNA-based Therapies
• By Application: Preclinical Services, Clinical Services, Commercial Manufacturing and Packaging

Regional Insights

• Largest Market in 2023: North America

The advanced therapeutics pharmaceutical outsourcing market is segmented by service type, indication, therapy, and application, with North America leading the market in 2023 due to its advanced infrastructure and high adoption of innovative therapies.

Request A Sample Of The Global Advanced Therapeutics Pharmaceutical Outsourcing Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=13768&type=smp